<DOC>
	<DOC>NCT03000673</DOC>
	<brief_summary>To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease treated with hemodialysis</brief_summary>
	<brief_title>A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Subjects with ESRD treated with hemodialysis 3 times a week for at least 3 months prior enrollment. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment. Women must not be breastfeeding Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) BMS986177 plus 5 halflives of study treatment (2 days) plus 30 days (duration of ovulatory cycle) for a total of 32 days posttreatment completion Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) BMS986177 plus 5 halflives of the study treatment plus 90 days (duration of sperm turnover) for a total of 92 days posttreatment completion. In addition, male participants must be willing to refrain from sperm donation during this time. Subjects receiving dialysis through central venous catheters History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease in the past 3 months Current or recent (within 3 months of study drug administration) gastrointestinal disease or surgery, which by the judgment of the Investigator, may increase a subject's risk of gastrointestinal bleeding or interfere with absorption of study drug (e.g., peptic or gastric ulcer disease, severe gastritis, history of gastrointestinal surgery). Any major surgery within 12 weeks of study drug administration History of significant head injury within the last 2 years, including subjects with base of skull fractures Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>